ISP Pharmaceuticals

Dr. Yunxia (Vivian) Bi has been appointed Technical Director of ISP Pharmaceuticals Solubility Initiative. In this newly created position, Dr. Bi will oversee development of technical data and information to support the use of ISP’s solubility-enhancing ingredient portfolio and solid dispersion development services by pharmaceutical formulators. Dr. Bi has experience in oral drug delivery systems formulated for bioavailability enhancement, and is author of more than 40 research papers and abstracts in formulation research. Prior to joining the company, Dr. Bi served as associate principal scientist at AstraZeneca.

“ISP is pleased to appoint a scientist with experience in confronting the challenges in developing poorly soluble drugs to lead this important R&D initiative. Dr. Bi knows the processes pharmaceutical makers follow when formulating poorly soluble entities and the general pathways pharmaceutical makers follow when commercializing such entities. We are confident Dr. Bi will be an asset to companies that want to reduce the development timeline and costs associated with the development of poorly soluble drugs,” said Philip Strenger, senior vice president Global Pharmaceuticals, ISP.